Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best healthcare stocks with the highest upside. Goldman Sachs initiated coverage of Soleno Therapeutics, Inc. (NASDAQ:SLNO) on October 7 with a Buy rating, assigning the stock a $125 price target.
The analyst told investors that Goldman Sachs expects Soleno Therapeutics, Inc.’s Vykat XR to become a “foundational treatment” for Prader-Willi syndrome.
According to the firm, the drug should expand into a blockbuster franchise, and the recent pullback provides investors with an attractive entry point into Soleno Therapeutics, Inc.’s shares.
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics to treat rare diseases. The company focuses on the treatment of neurobehavioral and metabolic disorders. Its lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet that treats Prader-Willi Syndrome (PWS).
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
